Therapy Detail

Therapy Name Salirasib
Therapy Description

Salirasib, S-trans,trans-farnesylthiosalycilic acid, disrupts the interaction of RAS with the cell membrane, thereby preventing RAS signaling (PMID: 20528225).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Salirasib KD032 RAS Inhibitor (Pan) 7 Salirasib, S-trans,trans-farnesylthiosalycilic acid, disrupts the interaction of RAS with the cell membrane, thereby preventing RAS signaling (PMID: 20528225).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS mutant lung adenocarcinoma no benefit Salirasib Phase II Actionable In a Phase II clinical trial, salirasib showed no benefit in KRAS-mutant lung adenocarcinoma patients (PMID: 21847063). 21847063
KRAS G13X Advanced Solid Tumor predicted - sensitive Salirasib Phase I Actionable In a Phase I clinical trial, Salirasib was well tolerated in Japanese patients with advanced solid tumors (n=21), and while the median progression-free survival (PFS) in the study overall was 53 days, patients harboring mutations in codon G12 or G13 of Kras (n=4) had a median PFS of 227 days (PMID: 29992354). 29992354
Unknown unknown Advanced Solid Tumor not applicable Salirasib Phase I Actionable In a Phase I clinical trial, Salirasib treatment was well tolerated in Japanese patients with advanced solid tumors (n=21) and resulted in a median progression-free survival of 53 days (PMID: 29992354). 29992354
KRAS G12X Advanced Solid Tumor predicted - sensitive Salirasib Phase I Actionable In a Phase I clinical trial, Salirasib was well tolerated in Japanese patients with advanced solid tumors (n=21), and while the median progression-free survival (PFS) in the study overall was 53 days, patients harboring mutations in codon G12 or G13 of Kras (n=4) had a median PFS of 227 days (PMID: 29992354). 29992354
Clinical Trial Phase Therapies Title Recruitment Status